By Deborah Erickson
In the world of primary care marketing, sheer marketing power—defined by total spend or number of reps—is often seen as...
Novartis's marketing now speaks as much to patients' emotional experiences of illness as to science or clinical benefit--and the shift is boosting sales.
By Deborah Erickson
In the world of primary care marketing, sheer marketing power—defined by total spend or number of reps—is often seen as...
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.